Innate Pharma (IPHYF) Other Non-Current Liabilities (2017 - 2025)
Historic Other Non-Current Liabilities for Innate Pharma (IPHYF) over the last 9 years, with Q2 2025 value amounting to $520701.4.
- Innate Pharma's Other Non-Current Liabilities rose 6446.41% to $520701.4 in Q2 2025 from the same period last year, while for Jun 2025 it was $520701.4, marking a year-over-year increase of 6446.41%. This contributed to the annual value of $292795.1 for FY2024, which is 5487.07% down from last year.
- Per Innate Pharma's latest filing, its Other Non-Current Liabilities stood at $520701.4 for Q2 2025, which was up 6446.41% from $292795.1 recorded in Q4 2024.
- In the past 5 years, Innate Pharma's Other Non-Current Liabilities registered a high of $648791.8 during Q4 2023, and its lowest value of $202009.0 during Q4 2022.
- Over the past 5 years, Innate Pharma's median Other Non-Current Liabilities value was $292795.1 (recorded in 2024), while the average stood at $372265.1.
- Per our database at Business Quant, Innate Pharma's Other Non-Current Liabilities surged by 22116.98% in 2023 and then crashed by 5487.07% in 2024.
- Over the past 5 years, Innate Pharma's Other Non-Current Liabilities (Quarter) stood at $289424.7 in 2021, then plummeted by 30.2% to $202009.0 in 2022, then soared by 221.17% to $648791.8 in 2023, then tumbled by 54.87% to $292795.1 in 2024, then soared by 77.84% to $520701.4 in 2025.
- Its last three reported values are $520701.4 in Q2 2025, $292795.1 for Q4 2024, and $316605.0 during Q2 2024.